UNSPSC 51183402: Mitiglinide

This classification denotes an anti-diabetic agent with the molecular formula C19H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D86I0XLB13, chemically known as (-)-(2s,3a,7a-cis)-alpha-benzylhexahydro-gamma-oxo-2-isoindolinebutyric acid but more generally known as mitiglinide, which bears US NIH Compound Identifier 3047758. European Medicines Agency schedules Mitiglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG.

UNSPSC 51183402 Mitiglinide, a Commodity code, covers the supply of this specific anti-diabetic pharmaceutical product to state and local government healthcare facilities through cooperative purchasing agreements. State and local procurement under this code focuses on securing generic pharmaceutical products through multi-source vendor agreements that establish pricing, supply chain compliance, and distribution partnerships with authorized pharmaceutical wholesalers. The issuing bodies are primarily state health departments, state purchasing offices administering cooperative purchasing alliances, and the member agencies and facilities (counties, municipalities, school districts, healthcare systems) that participate in those alliances. Work solicited under the code involves manufacturers and distributors certifying cGMP compliance, Drug Supply Chain Security Act (DSCSA) adherence, FDA registration, EDI capability, and pricing flexibility across multiple net-price formats and WAC-minus structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is driving recent activity with a multi-source pharmaceutical RFP issued January 20, 2026, extending across Minnesota, Oregon, and other participating member jurisdictions. MMCAP's solicitation (S1070000015802) closes March 26, 2026, and seeks manufacturers willing to establish two-year contracts effective July 1, 2026, with optional extensions through June 30, 2028. Evaluation emphasizes price competitiveness (75 percent), with remainder weighted on fixed pricing terms (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded vendors must maintain relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and carry commercial general liability coverage of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Specific award values are not disclosed; performance penalties range from $200 to $1,500 per violation for issues including late reporting or missed onboarding timelines.